Interferon Alfa

Summary

Interferon Alfa (CHEMBL2108506) is a phase-3 clinical-stage protein (ATC L03AB01); indicated across 51 conditions including neoplasm and cutaneous melanoma.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• ATC class: L03AB01
• Indications: 51 conditions
• Clinical trials: 16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108506
Name	Interferon Alfa
Type	Protein
Max phase	3
ATC	L03AB01

Also known as: Interferon alfa, Interferon alfa natural, INTERFERON ALFA, INTERFERON-ALFA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

51 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
cutaneous melanoma	3	MONDO:0005012	EFO:0000389
renal cell carcinoma	3	MONDO:0005086	EFO:0000681
melanoma	3	MONDO:0005105	EFO:0000756
plasma cell myeloma	3	MONDO:0009693	EFO:0001378
chronic hepatitis C virus infection	3	MONDO:0005354	EFO:0004220
hepatocellular carcinoma	3	MONDO:0007256	EFO:0000182
chronic myeloid leukemia	3	MONDO:0011996	EFO:0000339
clear cell renal carcinoma	3	MONDO:0005005	EFO:0000349
leukemia	3	MONDO:0005059	EFO:0000565
lymphoma	3	MONDO:0005062	EFO:0000574
papillary renal cell carcinoma	3	MONDO:0017884	EFO:0000640
acquired polycythemia vera	3	MONDO:0009891	EFO:0002429
hepatitis C virus infection	3	MONDO:0005231	EFO:0003047
head and neck cancer	3	MONDO:0005627	EFO:0006859
rectal cancer	3	MONDO:0006519	EFO:1000657
mantle cell lymphoma	3	MONDO:0018876	EFO:1001469
kidney cancer	3	MONDO:0002367	MONDO:0002367
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
skin neoplasm	3	MONDO:0002531	MONDO:0002898
essential thrombocythemia	3	MONDO:0005029	EFO:0000479
HIV infectious disease	3	MONDO:0005109	EFO:0000764
colorectal neoplasm	3	MONDO:0005335	MONDO:0005575
myelodysplastic syndrome	2	MONDO:0018881	EFO:0000198
osteosarcoma	2	MONDO:0009807	EFO:0000637
sarcoma	2	MONDO:0005089	EFO:0000691
exocrine pancreatic carcinoma	2	MONDO:0005192	EFO:0002618
mycosis fungoides	2	MONDO:0009691	EFO:1001051
myeloproliferative neoplasm	2	MONDO:0020076	EFO:0002428
central nervous system neoplasm	2	MONDO:0006130	EFO:1000158
neuroendocrine neoplasm	2	MONDO:0019496	EFO:1001901
gastric neoplasm	2	MONDO:0021085	MONDO:0001056
lung neoplasm	2	MONDO:0021117	MONDO:0008903
follicular lymphoma	2	MONDO:0018906	MONDO:0018906
type 1 diabetes mellitus	2	MONDO:0005147	MONDO:0005147
plasma cell neoplasm	2	MONDO:0004959	EFO:0000200
pulmonary fibrosis	2	MONDO:0002771	EFO:0009448
thrombocytopenia	2	MONDO:0002049	HP:0001873
mesothelioma	1	MONDO:0005065	EFO:0000588
peritoneal neoplasm	1	MONDO:0006901	MONDO:0002087
breast neoplasm	1	MONDO:0021100	MONDO:0007254
ovarian cancer	1	MONDO:0008170	MONDO:0008170
angiosarcoma	1	MONDO:0016982	EFO:0003968
triple-negative breast carcinoma	1	MONDO:0005494	EFO:0005537

7 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
PHASE3	9
PHASE1/PHASE2	2
Not specified	2
PHASE4	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04035837	PHASE4	ACTIVE_NOT_RECRUITING	The Clinical Cure Project of Chronic Hepatitis B in China
NCT06079879	PHASE3	RECRUITING	A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
NCT00004804	PHASE3	COMPLETED	Phase III Randomized Study of High Vs Standard Dose of Interferon Alfa for Chronic Hepatitis C
NCT00006237	PHASE3	COMPLETED	S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma
NCT00065468	PHASE3	COMPLETED	Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
NCT00083889	PHASE3	COMPLETED	SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
NCT00291369	PHASE3	COMPLETED	Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis
NCT00631371	PHASE3	COMPLETED	Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects
NCT00738530	PHASE3	COMPLETED	A Study of Avastin (Bevacizumab) Added to Interferon Alfa-2a (Roferon) Therapy in Patients With Metastatic Renal Cell Cancer With Nephrectomy
NCT04534725	PHASE3	COMPLETED	COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;
NCT00005615	PHASE1/PHASE2	COMPLETED	Post-Operative Adjuvant Radiotherapy With Concurrent Interferon-Alfa
NCT00363649	PHASE2	COMPLETED	Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI
NCT04072263	PHASE1/PHASE2	UNKNOWN	Adoptive T Cell Therapy in Patients With Recurrent Ovarian Cancer
NCT01220648	PHASE1	COMPLETED	Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)
NCT06926647	Not specified	NOT_YET_RECRUITING	A Real-World Study of Antiviral Therapy in Children With Chronic Hepatitis B
NCT03733652	Not specified	UNKNOWN	Optimal Treatment for Poor Efficacy of Entecavir in Chronic Hepatitis B Patients

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).